Product Introduction: TELTAN-MT 50

TELTAN-MT 50 is a combination anti-hypertensive medication manufactured by Ajantha. Composed of 40mg of Telmisartan (an angiotensin II receptor blocker) and 50mg of Metoprolol Succinate (a beta-blocker), it is indicated for the treatment of essential hypertension when monotherapy is insufficient, lowering blood pressure and reducing cardiovascular risks.

Primary Indications

• Treatment of essential hypertension (high blood pressure).
• Prevention of cardiovascular disease, reducing stroke and heart attack risk.
• Management of hypertension in patients with left ventricular hypertrophy.

Clinical Benefits

• Dual Action: Telmisartan relaxes blood vessels, while Metoprolol slows heart rate, lowering blood pressure.
• Cardioprotection: Significantly reduces cardiac preload and afterload, protecting against heart failure.
• Once-Daily Convenience: Offers reliable 24-hour blood pressure control with a single daily tablet.

Possible Side Effects

Common side effects may include:

• Dizziness, fatigue, headache, or orthostatic hypotension.
• Bradycardia (slow heart rate), cold extremities, or tiredness.
• Mild gastrointestinal discomfort or transient renal impairment.

How to Take TELTAN-MT 50

• Take one tablet daily, with or without food, preferably in the morning.
• Swallow the tablet whole with a glass of water.
• Do not stop taking the drug abruptly, as blood pressure can rise quickly.

Mechanism of Action

TELTAN-MT 50 works through two distinct mechanisms:

• Telmisartan: Selectively blocks the angiotensin II AT1 receptor, inhibiting vasoconstriction and aldosterone release, causing blood vessels to dilate.
• Metoprolol: A cardioselective beta-1 adrenergic receptor antagonist that reduces heart rate, myocardial contractility, and cardiac output, lowering systemic blood pressure.

Safety Warnings

• Pregnancy & Nursing: Strictly contraindicated. Angiotensin blockers can cause fetal injury or death.
• Liver Health: Since Telmisartan is extensively cleared by bile, use with caution in hepatic impairment.
• Kidney Health: Monitor renal function regularly, especially in patients with renal artery stenosis.

Patient Advice

• Avoid standing up too quickly from a sitting or lying position to prevent dizziness.
• Monitor your blood pressure regularly and keep a record.
• Avoid potassium supplements or salt substitutes unless directed by your physician.

Fact Box

Drug Interactions

• Lithium: May increase serum lithium concentrations and toxicity.
• NSAIDs (Ibuprofen): May reduce the blood-pressure-lowering effect.
• Potassium-Sparing Diuretics: May cause severe hyperkalemia.

User Feedback

• Patients report highly satisfactory blood pressure control, with a significant reduction in dizziness.
• Highly recommended by clinicians as a reliable combination therapy for essential hypertension.